News Sentiment

MDGL sentiment intelligence

Madrigal Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 553.48 Week of 17 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+3.1% over one week, +9.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 3.1% Price confirming higher
Trend fit Trend active 9.4% over four weeks
Fair value 67.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 26
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 7
simplywall.st 7
Simply Wall Street 3
Moomoo 2
GlobeNewswire 2
Investing.com 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 17
Analyst action 5
Deals and strategy 4
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Moomoo Direct company coverage

Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739

Citizens JMP has reiterated its Buy rating on Madrigal Pharmaceuticals (MDGL.US) but has reduced its target price to $739. The adjustment in the target price suggests a revised outlook on the company's valuation while maintaining a positive sentiment on its stock performance pote

Tone
Positive 58/100
Event
Analyst action
Published
17 Jul 2026 20:40
Source
Moomoo
GlobeNewswire Direct company coverage

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Madrigal Pharmaceuticals announced it will release its second-quarter 2026 financial results on July 30, 2026, before the U.S. financial markets open. Following the release, the company will host a live webcast at 8 a.m. Eastern Time to discuss its financial and operating results

Tone
Neutral 50/100
Event
Earnings
Published
17 Jul 2026 08:40
Source
GlobeNewswire
Simply Wall Street Direct company coverage

Is Madrigal Pharmaceuticals (MDGL) Fully Valued Ahead Of Its July 30 Earnings?

Madrigal Pharmaceuticals (MDGL) is approaching its Q2 2026 earnings release on July 30, with a current market value of US$12.7 billion. Despite recent share price momentum and a 5-year return of roughly 6x, the company is still considered 19.6% undervalued, with a fair value esti

Tone
Positive 66/100
Event
Earnings
Published
17 Jul 2026 04:11
Source
Simply Wall Street
Stock Titan Direct company coverage

Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30

Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, before U.S. markets open. Management will host a live webcast at 8:00 a.m. Eastern time to review the results, with a replay available approxima

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 12:10
Source
Stock Titan
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)

This article highlights bullish analyst ratings for three healthcare companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB), and Cadrenal Therapeutics, Inc. (CVKD). Analysts from Truist Financial, Goldman Sachs, and Noble Financial reiterated Buy ratings, providing price targe

Tone
Positive 73/100
Event
Analyst action
Published
15 Jul 2026 12:41
Source
The Globe and Mail
Moomoo Direct company coverage

Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says

Truist Securities has reiterated its Buy rating on Madrigal Pharmaceuticals (MDGL) after the company secured three new patents for its drug resmetirom. These patents are expected to extend the drug's exclusivity until 2045, enhancing its market position and providing long-term va

Tone
Positive 74/100
Event
Analyst action
Published
13 Jul 2026 22:42
Source
Moomoo
Investing.com Direct company coverage

Madrigal receives three new U.S. patents for resmetirom drug

Madrigal Pharmaceuticals Inc. has been granted three new U.S. patents for its drug resmetirom, marketed as Rezdiffra, which treats metabolic dysfunction-associated steatohepatitis (MASH). These patents cover treatment for F2/F3 fibrosis stages and well-compensated cirrhosis, exte

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 15:12
Source
Investing.com
GuruFocus Direct company coverage

Madrigal Pharmaceuticals (MDGL) Secures New Patents to Enhance Innovation

Madrigal Pharmaceuticals (MDGL) has secured three new patents for its drug resmetirom from the USPTO, strengthening its patent portfolio for long-term growth in the metabolic disease sector. While this bolsters its position for Rezdiffra, a treatment for MASH, the company's low G

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 13:10
Source
GuruFocus
Stock Titan Direct company coverage

New Rezdiffra patents extend Madrigal’s MASH IP into cirrhosis care

Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for its drug Rezdiffra (resmetirom). These patents strengthen its intellectual property portfolio for MASH treatment, specifically extending protection for F2/F3 MASH regimens until 2045 and 2042, and cover

Tone
Positive 91/100
Event
Market update
Published
13 Jul 2026 12:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Madrigal receives three new U.S. patents for resmetirom drug By Investing.com

Madrigal Pharmaceuticals Inc. has secured three new U.S. patents for its drug resmetirom (Rezdiffra), extending protection for treating F2/F3 fibrosis stages until 2045 and 2042, and F4c cirrhosis until 2042. This patent expansion coincides with the company's increased market cap

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 12:10
Source
Investing.com Canada
GlobeNewswire Direct company coverage

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Madrigal Pharmaceuticals announced the issuance of three new U.S. resmetirom patents by the USPTO, bolstering its intellectual property portfolio for Rezdiffra (resmetirom). These patents include two reinforcing protection for F2/F3 MASH patients and one for the potential F4c cir

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 12:10
Source
GlobeNewswire
DirectorsTalk Interviews Direct company coverage

Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Unpacking a 26.46% Potential Upside

Madrigal Pharmaceuticals, Inc. (MDGL) is a biotechnology company focused on metabolic dysfunction-associated steatohepatitis (MASH), with its flagship product Rezdiffra. Analysts are overwhelmingly bullish on MDGL, projecting a 26.46% potential upside from current levels, despite

Tone
Positive 72/100
Event
Guidance
Published
13 Jul 2026 09:12
Source
DirectorsTalk Interviews
Simply Wall Street Direct company coverage

Will siRNA MASH Candidate Nomination with Suzhou Ribo Change Madrigal Pharmaceuticals' (MDGL) Narrative?

Madrigal Pharmaceuticals' partnership with Suzhou Ribo Life Science has achieved a significant milestone with the nomination of a first candidate drug for RNA-based liver disease therapeutics targeting MASH. This development could broaden Madrigal's pipeline beyond its current dr

Tone
Positive 63/100
Event
Deals and strategy
Published
12 Jul 2026 15:40
Source
Simply Wall Street
Quiver Quantitative Direct company coverage

Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down

Madrigal Pharmaceuticals (MDGL) stock dropped 4.2% today, likely due to profit-taking after recent gains, rather than any clear negative company news. Despite the selloff, analysts maintain positive ratings and price targets, and the company reported continued pipeline progress a

Tone
Negative 39/100
Event
Market update
Published
10 Jul 2026 21:20
Source
Quiver Quantitative
Sahm Direct company coverage

Is Madrigal Pharmaceuticals (MDGL) Undervalued On Its New siRNA Milestone?

Madrigal Pharmaceuticals (MDGL) is gaining attention after its partner reported a new siRNA candidate drug for liver diseases, including MASH. Despite strong past performance and recent index upgrades, the stock's valuation is debated, with a popular narrative suggesting it is 19

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 17:41
Source
Sahm
Stock Traders Daily Direct company coverage

Trading the Move, Not the Narrative: (MDGL) Edition

This article analyzes Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines distinct institutional trading strategies, including position trading, momentum breakout, and risk hedging, based on AI

Tone
Positive 73/100
Event
Market update
Published
08 Jul 2026 17:38
Source
Stock Traders Daily
Insider Monkey Direct company coverage

BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)

BofA has lowered its price target for Madrigal Pharmaceuticals, Inc. (MDGL) to $542 from $550, while maintaining a Neutral rating. The revision comes after discussions with key opinion leaders, leading to a reduced 2028 Rezdiffra revenue forecast. Separately, Madrigal and Ribo ac

Tone
Neutral 50/100
Event
Analyst action
Published
08 Jul 2026 15:20
Source
Insider Monkey
Insider Monkey Direct company coverage

5 Best Under-the-Radar Stocks to Invest In

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is featured as one of the best under-the-radar stocks, with 47 hedge funds holding positions. BofA recently lowered its price target on MDGL due to slightly reduced revenue forecasts for Rezdiffra, though the drug’s launch in MASH has

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 00:41
Source
Insider Monkey
Market source Direct company coverage

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals announced the grant of equity inducement awards to seven new non-executive employees on July 1, 2026, totaling options to purchase 604 shares and 2,952 time-based restricted stock units. These awards were approved by the independent Compensation Committee

Tone
Positive 65/100
Event
Market update
Published
07 Jul 2026 06:09
Source
Market source
Stock Titan Direct company coverage

Madrigal gives seven new employees stock awards to join the company

Madrigal Pharmaceuticals granted equity inducement awards to seven new non-executive employees on July 1, 2026. These awards include 604 stock options and 2,952 time-based Restricted Stock Units (RSUs), with an exercise price of $514.39 per share, as part of the company's 2025 In

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:10
Source
Stock Titan
Simply Wall Street Direct company coverage

Will Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative

Madrigal Pharmaceuticals' investment narrative is largely centered on its drug Rezdiffra for MASH. The recent progression of its siRNA partnership with Suzhou Ribo Life Science into IND-enabling studies introduces a new RNA-based approach to its pipeline, diversifying its develop

Tone
Positive 65/100
Event
Deals and strategy
Published
04 Jul 2026 04:40
Source
Simply Wall Street
Finviz Direct company coverage

MDGL - Madrigal Pharmaceuticals Inc Latest SEC Filings

This article provides a detailed financial snapshot of Madrigal Pharmaceuticals Inc. (MDGL), including its latest stock performance, key financial metrics, insider and institutional ownership data, and various valuation ratios. It covers aspects like market capitalization, sales,

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 16:10
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL

The article displays the enterprise value to EBITDA forward for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). The content comes from TradingView, referencing financial data from ICE Data Services and FactSet, and SEC filings from Quartr.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 15:40
Source
TradingView
Stock Titan Direct company coverage

Madrigal and Ribo start IND-enabling studies after MASH milestone

Madrigal Pharmaceuticals and Suzhou Ribo Life Science have achieved a significant milestone in their siRNA partnership for liver disease, nominating a candidate drug for MASH (Metabolic Dysfunction-Associated Steatohepatitis). This triggers the immediate start of IND-enabling stu

Tone
Positive 72/100
Event
Deals and strategy
Published
02 Jul 2026 01:14
Source
Stock Titan
PR Newswire Direct company coverage

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Suzhou Ribo Life Science Co., Ltd. (Ribo) and Madrigal Pharmaceuticals, Inc. (Madrigal) have achieved their first major milestone in their siRNA partnership for metabolic dysfunction-associated steatohepatitis (MASH) therapies. This success involves the nomination of a candidate

Tone
Positive 73/100
Event
Deals and strategy
Published
02 Jul 2026 01:09
Source
PR Newswire